The laser-like national focus on reining in the cost of certain prescription drugs is beginning to produce thoughtful responses from all parties, although the pharmaceutical manufacturers may be less than enthusiastic about much of the activity.
Among the most ambitious: a proposed new rule by the Centers for Medicare and Medicaid Services that would test different ways of managing the cost of very expensive drugs based upon performance criteria. It targets drugs that are distributed either in physicians' offices or at hospitals, ones that tend to be expensive.
CMS wants to alter both the percent it pays out for Part B drugs for Medicare patients, and experiment with payments based upon "value-based purchasing tools similar to those employed by commercial health plans, pharmacy benefit managers, hospitals, and other entities that manage health benefits and drug utilization."
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Dan Cook
Dan Cook is a journalist and communications consultant based in Portland, OR. During his journalism career he has been a reporter and editor for a variety of media companies, including American Lawyer Media, BusinessWeek, Newhouse Newspapers, Knight-Ridder, Time Inc., and Reuters. He specializes in health care and insurance related coverage for BenefitsPRO.
